This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

The present invention relates to modified antibodies. In particular, the present invention relates to recombinant monoclonal antibodies having altered ability to induce direct cell death and effector function. In addition, the present invention relates to nucleic acid molecules encoding such antibodies, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the antibodies of the invention, and to methods of using these antibodies in treatment of disease.

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

A prophylactic and/or therapeutic food composition for control of bacterial and/or fungal infection in bees and/or bee larvae, and methods of using and making the same. Bee feed compositions comprising bacterial and/or fungal antibodies dispersed in an edible base composition. Use of bacterial and/or fungal antigenic agents to passively generate bacterial and/or fungal antibodies in chicken egg yolks, and use of such bacterial and/or fungal antibodies for prophylaxis or treatment of bacterial and/or fungal infection in the bees and/or larvae.

A prophylactic and/or therapeutic food composition for control of bacterial and/or fungal infection in bees and/or bee larvae, and methods of using and making the same. Bee feed compositions comprising bacterial and/or fungal antibodies dispersed in an edible base composition. Use of bacterial and/or fungal antigenic agents to passively generate bacterial and/or fungal antibodies in chicken egg yolks, and use of such bacterial and/or fungal antibodies for prophylaxis or treatment of bacterial and/or fungal infection in the bees and/or larvae.

Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.

Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.